AU1518492A - Pharmaceutical compositions for transcutaneous administration - Google Patents

Pharmaceutical compositions for transcutaneous administration

Info

Publication number
AU1518492A
AU1518492A AU15184/92A AU1518492A AU1518492A AU 1518492 A AU1518492 A AU 1518492A AU 15184/92 A AU15184/92 A AU 15184/92A AU 1518492 A AU1518492 A AU 1518492A AU 1518492 A AU1518492 A AU 1518492A
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
transcutaneous administration
transcutaneous
administration
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU15184/92A
Other versions
AU649130B2 (en
Inventor
Herbert Bippi
Jurgen C. Frolich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of AU1518492A publication Critical patent/AU1518492A/en
Application granted granted Critical
Publication of AU649130B2 publication Critical patent/AU649130B2/en
Assigned to RATIOPHARM GMBH reassignment RATIOPHARM GMBH Alteration of Name(s) in Register under S187 Assignors: BIPPI, HERBERT, FROLICH, JURGEN C.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Prostaglandin E1 derivatives as pharmacological active compounds and medicaments containing these compounds are described, in particular for transcutaneous application.
AU15184/92A 1987-02-16 1992-04-24 Pharmaceutical compositions for transcutaneous administration Ceased AU649130B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3704825 1987-02-16
DE19873704825 DE3704825A1 (en) 1987-02-16 1987-02-16 PROSTAGLANDIN E1 DERIVATIVES AS PHARMACEUTICAL ACTIVE SUBSTANCES AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, IN PARTICULAR FOR TRANSCUTANEAL USE

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU11766/88A Division AU623336B2 (en) 1987-02-16 1988-02-16 Method of treatment comprising transcutaneous administration of prostaglandin E1 derivatives

Publications (2)

Publication Number Publication Date
AU1518492A true AU1518492A (en) 1992-06-25
AU649130B2 AU649130B2 (en) 1994-05-12

Family

ID=6321070

Family Applications (2)

Application Number Title Priority Date Filing Date
AU11766/88A Ceased AU623336B2 (en) 1987-02-16 1988-02-16 Method of treatment comprising transcutaneous administration of prostaglandin E1 derivatives
AU15184/92A Ceased AU649130B2 (en) 1987-02-16 1992-04-24 Pharmaceutical compositions for transcutaneous administration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU11766/88A Ceased AU623336B2 (en) 1987-02-16 1988-02-16 Method of treatment comprising transcutaneous administration of prostaglandin E1 derivatives

Country Status (11)

Country Link
EP (1) EP0292643B1 (en)
JP (1) JPS63246331A (en)
AT (1) ATE80616T1 (en)
AU (2) AU623336B2 (en)
CA (1) CA1327359C (en)
DE (2) DE3704825A1 (en)
DK (1) DK173552B1 (en)
ES (1) ES2043696T3 (en)
GR (1) GR3005743T3 (en)
HU (1) HU199687B (en)
ZA (1) ZA881053B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2939569A (en) * 1957-10-16 1960-06-07 Gay W Roach Cotton weighing machine
AU674054B2 (en) * 1993-02-03 1996-12-05 Teijin Limited Dermatologic preparation composition containing isocarbacyclin as active ingredient
CA2133334A1 (en) * 1993-02-03 1994-08-04 Atsuo Hazato External skin treatment agent composition containing prostacyclins as active ingredient
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
FR2812192B1 (en) * 2000-07-28 2003-01-31 Oreal USE OF PROSTAGLANDIN EP-3 RECEPTOR ANTAGONISTS AS A COSMETIC AGENT FOR MITIGATING, REDUCING OR STOPPING HAIR AND HAIR LOSS
FR2812191B1 (en) * 2000-07-28 2003-10-17 Oreal USE OF PROSTAGLANDIN E2 RECEPTOR AGONISTS (EP-3) TO ATTENUATE, DECREASE OR STOP HAIR AND HAIR GROWTH IN COSMETIC PREPARATIONS
FR2812190B1 (en) * 2000-07-28 2003-01-31 Oreal USE OF NON-PROSTANOIC AGONISTS OF EP-2 AND / OR EP-4 PROSTAGLANDIN RECEPTORS AS A COSMETIC AGENT FOR MITIGATING, DECREASING OR STOPPING HAIR AND HAIR LOSS
FR2812193B1 (en) * 2000-07-28 2003-10-24 Oreal USE OF AN ANTAGONIST OF PROSTAGLANDIN EP-2 AND / OR EP-4 RECEPTORS TO ATTENUATE, DECREASE OR STOP HAIR AND HAIR GROWTH IN COSMETIC PREPARATIONS
CN1777429A (en) 2003-04-02 2006-05-24 尼克美制药控股有限公司 Prostaglandin compositions and applications for the treatment of vasospasm
IT1402047B1 (en) * 2010-10-19 2013-08-28 Cross Pharma Sa USE OF MEXIPROSTIL IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES
RU2633236C2 (en) 2011-04-07 2017-10-11 Нексмед Холдингс, Инк. Methods and compositions for raynaud disease treatment
US10383839B2 (en) 2011-06-30 2019-08-20 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
ITRM20120036A1 (en) * 2012-02-02 2013-08-03 Robert Davis Steigerwalt Jr TRANSDERMAL APPLICATION OF PROSTAGLANDINE E1 FOR THE TREATMENT OF OCULAR ISCHEMIA.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3735005A (en) * 1970-08-19 1973-05-22 Alza Corp Method for preparing a viable platelet concentrate
US4205178A (en) * 1976-12-30 1980-05-27 The Upjohn Company 6-Keto prostaglandin E-type compounds
AU511711B2 (en) * 1976-12-30 1980-09-04 Upjohn Company, The 6-Oxo and 5, 6-Dihalo prostaglandin analogues
JPS6022710B2 (en) * 1977-09-16 1985-06-03 小野薬品工業株式会社 Prostaglandin-like compounds
JPS59216820A (en) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd Fat emulsion of prostaglandin
US4707495A (en) * 1985-10-28 1987-11-17 Ortho Pharmaceutical Peptic ulcer treatment method

Also Published As

Publication number Publication date
DE3874610D1 (en) 1992-10-22
CA1327359C (en) 1994-03-01
JPS63246331A (en) 1988-10-13
AU649130B2 (en) 1994-05-12
AU623336B2 (en) 1992-05-14
EP0292643A1 (en) 1988-11-30
GR3005743T3 (en) 1993-06-07
ZA881053B (en) 1988-08-12
ATE80616T1 (en) 1992-10-15
DE3704825A1 (en) 1988-08-25
HUT46224A (en) 1988-10-28
DK173552B1 (en) 2001-02-26
HU199687B (en) 1990-03-28
ES2043696T3 (en) 1994-01-01
EP0292643B1 (en) 1992-09-16
AU1176688A (en) 1988-08-18
DK77588A (en) 1988-08-17
DK77588D0 (en) 1988-02-15

Similar Documents

Publication Publication Date Title
AU6194694A (en) Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
ES8104720A1 (en) Preparations for parenteral administration of fat-soluble drugs.
AU6542986A (en) Pyridyl-methylthio substituted benzimidazoles
IE894048L (en) New therapeutically active compound and a process for its¹preparation
AU7076887A (en) Nasal administration of drugs
IL108071A0 (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines their preparation and pharmaceutical compositions containing them
IL89748A (en) Pharmaceutical compositions for systemic transdermal administration, containing deprenyl
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
EP0279149A3 (en) Benzimidazole derivatives, process for their production and a pharmaceutical composition containing the same
HUT46657A (en) Process for producing antitumour pharmaceutical compositions comprising sulfonyl-urea derivatives as active ingredient
AU1518492A (en) Pharmaceutical compositions for transcutaneous administration
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
AU2293488A (en) Alkadiene derivatives, their preparation, and pharmaceutical compositions containing them
AU2617288A (en) Pharmaceutical formulations for transdermal administration
HUT63151A (en) Process for producing new benzimidazole-2-sulfonamide and imidazopyuridine-2-sylfonamide derivatives, as well as pharmaceutical compositions comprising same as active ingredient
AU2231688A (en) Stabilisation of therapeutically active proteins in a pharmaceutical composition
IE56229B1 (en) 2-piperazinyl-or-homopiperazinyl-quinazoline derivatives their production and pharmaceutical compositions containing them
IL76345A0 (en) Proline derivatives and antihypertensive and anti-glaucoma pharmaceutical preparations containing the same
IL106289A0 (en) Phospholipid derivatives, their preparation and pharmaceutical compositions containing them
IL106107A (en) Imidazolyl-substituted cyclohexane derivatives, their preparation and pharmaceutical compositions containing them
MX9305578A (en) ADSORBATE BASED ON A MIXTURE OF AUXILIARY SUBSTANCES AND A SOLID ACTIVE PRINCIPLE FOR THE PRODUCTION OF DRUG PREPARATIONS.
AU4154993A (en) New peptide compounds active in cell adhesion processes, a process for the preparation thereof, and pharmaceutical compositions containing them
JO1531B1 (en) Novel pharmacological compounds
FR2567755B1 (en) NEW ANTI-TUMOR DRUG CONTAINING TRIACETOXY-1,8,9 ANTHRACENE AS ACTIVE INGREDIENT
JO1519B1 (en) Novel compounds (Novel deravatives of Benzimidazoles active as anti-ulcer agents).